Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences The RNA Summit: Research, Diagnostics & Therapeutics

Carl Novina's Biography

Carl Novina, Associate Professor of Medicine, Dana-Farber Cancer Institute and Harvard Medical School; Associate Member, The Broad Institute of MIT & Harvard

Carl D. Novina MD, PhD is an Associate Professor of Medicine at the Dana-Farber Cancer Institute & Harvard Medical School and an Associate Member of the Broad Institute of Harvard and MIT. He received his M.D. from Columbia University, College of Physicians and Surgeons and his Ph.D. from Tufts University, Sackler School of Graduate Biomedical Sciences. He completed his postdoctoral fellowship at the Massachusetts Institute of Technology in the laboratory of Nobel Laureate Dr. Phillip Sharp.

Dr. Novina’s laboratory has made several important discoveries into the biology of noncoding RNAs, their dysregulation in cancers, and their development as biomedical tools. More recently, his laboratory has developed tools for cellular engineering, including tools that enable targeted DNA methylation and T cell-directed immunotherapy. He has established many collaborations between industry partners and physicians to facilitate his goal of bringing biomedical innovations from bench to bedside.

Dr. Novina is the recipient of numerous awards and honors including the Doris Duke Clinical Scientist Development Award, American Cancer Society Research Scholar Award, W.M. Keck Distinguished Young Scholars Award, Department of Defense Idea Award, The NCI Director’s Provocative Questions Award, and the National Science Foundation Collaborative Research Project Award. He is also the recipient of the prestigious NIH Director’s Pioneer Award, which funds high-risk research with transformative potential.

Carl Novina Image

Lnc’ing Non-coding RNAs to Melanoma Biology

Monday, 13 November 2017 at 17:00

Add to Calendar ▼2017-11-13 17:00:002017-11-13 18:00:00Europe/LondonLnc’ing Non-coding RNAs to Melanoma BiologyThe RNA Summit: Research, Diagnostics and Therapeutics in Boston, USABoston,

Long non-coding RNAs (lncRNAs) are critical regulators of numerous physiological processes and diseases, especially cancers. The tissue- and disease-specific expression of lncRNAs, as well as their gene-regulatory functions, makes lncRNAs ideal therapeutic targets. However, development of lncRNA-based cancer therapies is limited because the mechanisms of many lncRNAs are obscure. We identified a novel lncRNA, SLNCR, whose expression is associated with worse overall melanoma survival. SLNCR contains a highly-conserved sequence that binds to the androgen receptor (AR) and mediates increased melanoma invasion and proliferation in an androgen-independent manner. Thorough biochemical characterization of the AR-RNA interaction reveals that the N-terminal regulatory domain of AR binds to single-stranded RNA in a sequence-specific manner. To develop candidate therapeutics inhibiting the SLNCR- and AR-mediated invasion and proliferation, we designed 21-28 nucleotide oligos that are the (i) reverse complement to SLNCR’s AR binding sequence, which bind to SLNCR to generate double stranded RNA incapable of AR binding; or (ii) mimics of the SLNCR AR binding sequence, which bind directly to AR to preclude SLNCR binding. Both SLNCR- and AR-binding oligos are capable of sterically blocking the AR-SLNCR association. Delivery of these oligos to patient-derived melanoma cells reduces melanoma invasion and proliferation. Thus, these SLNCR- and AR-binding oligos represent novel therapeutic approaches for inhibition of melanoma growth and metastasis.

Add to Calendar ▼2017-11-13 00:00:002017-11-14 00:00:00Europe/LondonThe RNA Summit: Research, Diagnostics and TherapeuticsThe RNA Summit: Research, Diagnostics and Therapeutics in Boston, USABoston,